These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 36281654

  • 1. 18 F-DCFPyL positron emission tomography/magnetic resonance imaging-guided ultrasound fusion biopsy is an identical pathway in prostate cancer diagnosis.
    Niu S, Liu Y, Ding X, Xu Y, Yu H, Feng X, Chang X, Wang H, Li J, Gong H, Ao L, Liu J, Lin M, Wang B, Ma X, Xu B, Zhang X.
    Prostate; 2023 Feb; 83(2):142-150. PubMed ID: 36281654
    [Abstract] [Full Text] [Related]

  • 2. Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study.
    Bodar YJL, Zwezerijnen BGJC, van der Voorn PJ, Jansen BHE, Smit RS, Kol SQ, Meijer D, de Bie K, Yaqub M, Windhorst BAD, Hendrikse HNH, Vis AN, Oprea-Lager DE.
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1731-1742. PubMed ID: 34725727
    [Abstract] [Full Text] [Related]

  • 3. [18F]-DCFPyL Positron Emission Tomography/Magnetic Resonance Imaging for Localization of Dominant Intraprostatic Foci: First Experience.
    Bauman G, Martin P, Thiessen JD, Taylor R, Moussa M, Gaed M, Rachinsky I, Kassam Z, Chin J, Pautler S, Lee TY, Valliant JF, Ward A.
    Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
    [Abstract] [Full Text] [Related]

  • 4. Comparison between 18 F-DCFPyL PET and MRI for the detection of transition zone prostate cancer.
    Liu Y, Dong Y, Liu J, Zhang X, Lin M, Xu B.
    Prostate; 2021 Dec; 81(16):1329-1336. PubMed ID: 34516670
    [Abstract] [Full Text] [Related]

  • 5. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.
    Piert M, Montgomery J, Kunju LP, Siddiqui J, Rogers V, Rajendiran T, Johnson TD, Shao X, Davenport MS.
    J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061
    [Abstract] [Full Text] [Related]

  • 6. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
    van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C, Barentsz JO.
    Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
    [Abstract] [Full Text] [Related]

  • 7. Prospective Evaluation of 18F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI.
    Gaur S, Mena E, Harmon SA, Lindenberg ML, Adler S, Ton AT, Shih JH, Mehralivand S, Merino MJ, Wood BJ, Pinto PA, Mease RC, Pomper MG, Choyke PL, Turkbey B.
    AJR Am J Roentgenol; 2020 Sep; 215(3):652-659. PubMed ID: 32755168
    [Abstract] [Full Text] [Related]

  • 8. Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer.
    Bodar YJL, Boevé LMS, van Leeuwen PJ, Baars PC, Nieuwenhuijzen JA, van Haarst EP, Oddens JR, Donswijk ML, van Riel LAMJG, Scheltema MJ, Meijer D, Hendrikse NH, Oprea-Lager DE, Vis AN.
    BJU Int; 2023 Dec; 132(6):705-712. PubMed ID: 37620288
    [Abstract] [Full Text] [Related]

  • 9. Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies.
    Maxeiner A, Nest AM, Stephan C, Cash H, Baur ADJ, Fischer T, Kilic E, Piper SK, Nowak CP, Busch J, Miller K, Mang J.
    Urol Int; 2020 Dec; 104(3-4):205-213. PubMed ID: 31801153
    [Abstract] [Full Text] [Related]

  • 10. Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen.
    Lian H, Zhuang J, Wang W, Zhang B, Shi J, Li D, Fu Y, Jiang X, Zhou W, Guo H.
    BMC Urol; 2017 Jul 05; 17(1):52. PubMed ID: 28679370
    [Abstract] [Full Text] [Related]

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jul 05; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 12. Performance of Combined Magnetic Resonance Imaging/Ultrasound Fusion-guided and Systematic Biopsy of the Prostate in Biopsy-naïve Patients and Patients with Prior Biopsies.
    Preisser F, Theissen L, Wenzel M, Humke C, Bodelle B, Köllermann J, Kluth L, Banek S, Becker A, Roos F, Chun FK, Mandel P.
    Eur Urol Focus; 2021 Jan 05; 7(1):39-46. PubMed ID: 31296485
    [Abstract] [Full Text] [Related]

  • 13. Enhancing prostate cancer diagnosis and reducing unnecessary biopsies with [18F]DCFPyL PET/CT imaging in PI-RADS 3/4 patients.
    Fu Y, Zhao M, Chen J, Wen Q, Chen B.
    Sci Rep; 2024 Jul 05; 14(1):15525. PubMed ID: 38969741
    [Abstract] [Full Text] [Related]

  • 14. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
    Meng X, Rosenkrantz AB, Mendhiratta N, Fenstermaker M, Huang R, Wysock JS, Bjurlin MA, Marshall S, Deng FM, Zhou M, Melamed J, Huang WC, Lepor H, Taneja SS.
    Eur Urol; 2016 Mar 05; 69(3):512-7. PubMed ID: 26112001
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK, Gayet M, Verbeek JF, Engelbrecht MRW, Savci-Heijink CD, Jager GJ, Gielens MPM, van der Linden H, Beerlage HP, de Reijke TM, Wijkstra H, Roobol MJ.
    Eur Urol Oncol; 2018 Jun 05; 1(2):109-117. PubMed ID: 31100233
    [Abstract] [Full Text] [Related]

  • 18. Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial.
    Bodar YJL, Jansen BHE, van der Voorn JP, Zwezerijnen GJC, Meijer D, Nieuwenhuijzen JA, Boellaard R, Hendrikse NH, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN.
    World J Urol; 2021 Jul 05; 39(7):2439-2446. PubMed ID: 33079250
    [Abstract] [Full Text] [Related]

  • 19. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.
    Kuru TH, Roethke MC, Seidenader J, Simpfendörfer T, Boxler S, Alammar K, Rieker P, Popeneciu VI, Roth W, Pahernik S, Schlemmer HP, Hohenfellner M, Hadaschik BA.
    J Urol; 2013 Oct 05; 190(4):1380-6. PubMed ID: 23608676
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.